UBS Group Upgrades Jazz Pharmaceuticals (NASDAQ:JAZZ) to Buy

UBS Group upgraded shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) from a neutral rating to a buy rating in a research report sent to investors on Friday, Marketbeat.com reports. They currently have $179.00 price objective on the specialty pharmaceutical company’s stock, up from their prior price objective of $145.00.

A number of other research firms have also commented on JAZZ. Needham & Company LLC restated a “buy” rating and issued a $210.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday. Robert W. Baird boosted their price target on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research report on Monday, November 18th. Wells Fargo & Company upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $130.00 to $170.00 in a research report on Thursday, February 13th. Truist Financial boosted their price target on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Piper Sandler restated an “overweight” rating and issued a $176.00 price target (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $189.40.

Jazz Pharmaceuticals Price Performance

Shares of Jazz Pharmaceuticals stock opened at $138.81 on Friday. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The firm’s 50-day simple moving average is $128.14 and its 200-day simple moving average is $120.00. Jazz Pharmaceuticals has a twelve month low of $99.06 and a twelve month high of $148.06. The firm has a market cap of $8.43 billion, a P/E ratio of 19.55, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44.

Insider Buying and Selling

In related news, CMO Robert Iannone sold 7,080 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $138.60, for a total transaction of $981,288.00. Following the completion of the sale, the chief marketing officer now directly owns 82,024 shares of the company’s stock, valued at $11,368,526.40. The trade was a 7.95 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Bruce C. Cozadd sold 6,500 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $144.25, for a total transaction of $937,625.00. Following the sale, the chief executive officer now directly owns 464,058 shares of the company’s stock, valued at approximately $66,940,366.50. This trade represents a 1.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 25,193 shares of company stock valued at $3,533,122 over the last ninety days. Insiders own 4.20% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. IFP Advisors Inc bought a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth approximately $25,000. Quadrant Capital Group LLC grew its holdings in Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after purchasing an additional 101 shares during the period. Elequin Capital LP grew its holdings in Jazz Pharmaceuticals by 677.8% during the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 183 shares during the period. CoreFirst Bank & Trust acquired a new position in Jazz Pharmaceuticals during the fourth quarter valued at approximately $28,000. Finally, Allianz SE acquired a new position in Jazz Pharmaceuticals during the fourth quarter valued at approximately $29,000. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.